Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Medicine, Lung cancer, Internal medicine, Oncology, Cancer research, and Crizotinib.
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Response to targeted and immune therapy in patients with NSCLC and BRAF non-V600E mutations: A retrospective, multicenter analysis within the national Network Genomic Medicine Lung Cancer (nNGM) in Germany.
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of <i>EGFR</i> -Mutant and <i>RET</i> Fusion-Positive Lung Cancers
Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysis
MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations
How previous treatment changes the metabolomic profile in patients with metastatic breast cancer
On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer
FP14.07 Combination Osimertinib plus Selpercatinib for EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) with Acquired RET fusions
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
A plasma metabolite panel as biomarkers for early primary breast cancer detection
Identification of a blood based metabolomic classifer for the detection of ovarian cancer – MeDOC
Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma
<i>ROS1</i> rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability
Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon <i>EGFR</i> Mutations Pretreated With Reversible EGFR Inhibitors